UNITED THERAPEUTICS CORP (UTHR) Stock Price, Quote, News and Overview
NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD
UTHR Quote, Performance and Key Statistics
UNITED THERAPEUTICS CORP
NASDAQ:UTHR (2/5/2025, 11:45:12 AM)
357.98
+4.55 (+1.29%)
The current stock price of UTHR is 357.98 USD. In the past month the price decreased by -0.81%. In the past year, price increased by 66.45%.
UTHR Latest News, Press Releases and Analysis
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
FDA Greenlights Studies of Pig Kidney Transplants in Humans
The US Food and Drug Administration approved clinical trials that will transplant organs from genetically modified pigs into patients with kidney failure.
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
UTHR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.94 | 338.80B | ||
| AMGN | AMGEN INC | 15.36 | 163.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 954.43 | 125.36B | ||
| GILD | GILEAD SCIENCES INC | 22.56 | 124.55B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.49 | 77.67B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.44B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.41B | ||
| NTRA | NATERA INC | N/A | 23.31B | ||
| BIIB | BIOGEN INC | 8.94 | 21.28B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.76B |
Related stock screener links
About UTHR
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,168 full-time employees. The company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Company Info
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910 US
CEO: Martine A. Rothblatt
Employees: 1168
Company Website: https://www.unither.com/
Investor Relations: https://ir.unither.com/
Phone: 13016089292
UTHR FAQ
What is the stock price of UTHR?
The current stock price of UTHR is 357.98 USD.
What is the symbol for UNITED THERAPEUTICS CORP stock?
The exchange symbol of UNITED THERAPEUTICS CORP is UTHR and it is listed on the Nasdaq exchange.
On which exchange is UTHR stock listed?
UTHR stock is listed on the Nasdaq exchange.
Is UTHR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for UTHR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of UTHR.
Does UTHR stock pay dividends?
UTHR does not pay a dividend.
When does UTHR stock report earnings?
UTHR will report earnings on 2025-02-19, after the market close.
What is the Price/Earnings (PE) ratio of UTHR?
The PE ratio for UTHR is 15.72. This is based on the reported non-GAAP earnings per share of 22.77 and the current share price of 357.98 USD.
What is the Short Interest ratio of UTHR stock?
The outstanding short interest for UTHR is 4.51% of its float.
UTHR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to UTHR. When comparing the yearly performance of all stocks, UTHR is one of the better performing stocks in the market, outperforming 87.41% of all stocks.
UTHR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to UTHR. UTHR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
UTHR Financial Highlights
Over the last trailing twelve months UTHR reported a non-GAAP Earnings per Share(EPS) of 22.77. The EPS decreased by 25.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 40.31% | ||
| ROA | 15.6% | ||
| ROE | 18.21% | ||
| Debt/Equity | 0 |
UTHR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to UTHR. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 28.8% and a revenue growth 25.67% for UTHR